GLI2 Transcription Factor Modulates CD40 Ligand Expression In Bone Marrow Stromal Cells »
05/12/14

Lenalidomide/Rituximab Maintenance After Induction With Fludarabine/Rituximab In Combination With Escalating Doses Of Lenalidomide In Previously Untreated Chronic Lymphocytic Leukemia (CLL): The Revlirit CLL5 AGMT Phase I/II Study, Final Results »
05/12/14

IGHV Mutation Status Does Not Add Prognostic Information In The Background Of Mutations In TP53 and SF3B1, and Deletions Of 17p and 11q, Which Are Independent Adverse Prognostic Parameters In CLL. »
05/12/14

The Novel Proteasome Inhibitor MLN2238 (Ixazomib) Induces Death In CLL Cells In Vitro and Potentiates Lethality Of Fludarabine and The BCL2 Inhibitor At-101 »
05/12/14

Enhanced IgG Hexamerization Mediates Efficient C1q Docking and Complement-Dependent Cytotoxicity; Preclinical Proof Of Concept On Primary CLL and Burkitt Lymphoma. »
05/12/14

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib and Rituximab for Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL) »
05/12/14

Clinical Impact Of Small TP53 Mutated Subclones In Chronic Lymphocytic Leukemia. »
05/12/14

STAT3-Activated GM-CSFRI± Shuttles To The Nucleus and Protects CLL Cells From Apoptosis »
05/12/14

Bcl-2 Inhibitor ABT-199 (GDC-0199) Monotherapy Shows Anti-Tumor Activity Including Complete Remissions In High-Risk Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) »
05/12/14

Dietary methionine deprivation enhanced the antitumor effects of lexatumumab in an orthotopic metastatic TNBC model. »
03/01/15